Abstracto

Short Review on Dapagliflozin

Vishnu Vardhan

Dapagliflozin is a medication of the gliflozin class, used to treat type 2 diabetes. It was produced by Bristol-Myers Squibb in organization with AstraZeneca. Dapagliflozin is a sodium-glucose cotransporter 2(SGLT2) inhibitor. It works by diminishing the measure of sugar the body assimilates and expanding the measure of sugar that leaves the body. Dapagliflozin is utilized alongside diet and work out, and now and again with different drugs, to lower glucose levels in patients with type 2 diabetes (condition in which glucose is too high in light of the fact that the body does not create or utilize insulin ordinarily). Dapagliflozin is in a class of drugs called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It brings down glucose by creating the kidneys to dispose of more glucose. Dapagliflozin is not used to treat type 1 diabetes (condition in which the body does not deliver insulin and, in this manner, can't control the measure of sugar in the blood) or diabetic ketoacidosis (a genuine condition that may create if high glucose is not treated).

Descargo de responsabilidad: este resumen se tradujo utilizando herramientas de inteligencia artificial y aún no ha sido revisado ni verificado.

Indexado en

Google Académico
Open J Gate
ResearchBible
CiteFactor
Cosmos SI
Índice de revistas académicas abiertas (OAJI)
director académico
Publons
Factor de impacto de revistas innovadoras internacionales (IIJIF)
Instituto Internacional de Investigación Organizada (I2OR)
Cosmos
Fundación de Ginebra para la educación e investigación médicas
Laboratorios secretos de motores de búsqueda
Pub Europeo

Ver más